The global immunology market is projected to nearly double by 2032, expanding from $250 billion in 2023. Immunology and Inflammation (I&I) has now emerged as a top investment priority in biopharma, surpassing oncology in growth. This surge is fueled by groundbreaking innovations from both biotech and pharma. In this panel, leaders from four pioneering biotech and pharma companies, along with a leading venture capitalist, will explore the key scientific advancements, emerging platforms, and breakthrough technologies driving I&I growth. They will also discuss which innovations are attracting major investments and strategic industry partnerships, shaping the future of this rapidly evolving field.